• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Minn. legislators to FDA: Don’t tread on device makers

Minn. legislators to FDA: Don’t tread on device makers

May 28, 2010 By MedCity News

MedCity News logo

A pair of Minnesota legislators are lobbying against changes the Food & Drug Administration proposes for its 510(k) clearance protocol the industry says will hurt innovation and the state’s economy.

U.S. Sen. Amy Klobuchar (D:Minn.) and Rep. Erik Paulsen (R:Minn.) sent a letter to FDA Commissioner Dr. Margaret Hamburg, warning that overzealous regulation would hurt start-ups struggling to raise venture capital in a weak economy.

Sen. Amy Klobuchar (D:Minn.)

Klobuchar

Rep. Erik Paulsen (R:Minn.)

Paulsen

“Bringing a new medical device to market typically involves millions, sometimes hundreds of millions, of dollars in upfront research and development costs,” wrote Klobuchar, chair of the Senate Commerce Subcommittee on Competitiveness, Innovation and Export Promotion, and Paulsen, chair of the Medical Technology Caucus. “The suggested changes could threaten the availability of often relied on equity investments.”

Calls to both Klobuchar’s and Paulsen’s offices seeking an explanation of the specific changes to the 510(k) program that concern the legislators were not immediately returned.

The letter comes about a week after Dr. Jeffrey Shuren, director of the agency’s Center for Devices and Radiological Health, met with local industry officials in a town hall forum in Bloomington, Minn.

Here’s the full text of the letter:

May 25, 2010

Dr. Margaret Hamburg
Commissioner
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002

Dear Dr. Hamburg,

Thank you for your service in your role as Commissioner of the Food and Drug Administration (FDA). We are writing to express concerns regarding the FDA’s proposed changes to the 510 (k) approval process for medical devices.

This is an issue of particular importance to our home state of Minnesota. Our state has led medical innovation for more than 60 years and boasts more than 400 medical device companies that together employ over 50,000 people. In the last few weeks, we’ve had the opportunity to speak with a number of medical device companies, many of which attended the FDA’s town hall meeting on May 18, 2010 in Bloomington, Minnesota regarding recent changes in the FDA’s approval process.

We support your agency’s goal to improve the FDA’s policies and procedures to ensure only safe and effective devices reach the marketplace. We also applaud your willingness to meet personally with our state’s medical device industry to discuss how they can have the most productive collaboration. This is essential for American patients to continue to have access to the best, most advanced medical technology possible.

However, we are concerned that some policy changes under consideration by the FDA would add new and unnecessary regulations, resulting in an even longer and more complicated approval process.

In addition to creating an undue regulatory burden, these changes would increase the time, cost and risk associated with developing new medical technology.

Bringing a new medical device to market typically involves millions, sometimes hundreds of millions, of dollars in upfront research and development costs. The suggested changes could threaten the availability of often relied on equity investments. Already, FDA’s increasingly slow and inconsistent approval system has dampened investment in small medical device firms. In the last two years, venture capital funding alone dropped by one-third. Efforts to further restrict the approval process would only compound those declines, jeopardizing 83% of jobs in the medical technology sector and threatening our nation’s $5.4 billion trade surplus in medical device exports.

For decades, the FDA and the medical device industry enjoyed a successful partnership– one that allowed them to ensure new products were appropriately vetted, and innovative technologies were adequately supported. We urge the FDA to maintain that tradition of cooperation today, and to reject proposals that unduly burden small businesses and suppress the development of promising medical breakthroughs.

Thank you for your consideration of this important issue.

Sincerely,

Amy Klobuchar
United States Senator

Erik Paulsen
United States Representative

Filed Under: Business/Financial News, Food & Drug Administration (FDA), News Well Tagged With: Gift Bans

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy